Literature DB >> 16023620

The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R).

Ronald C Kessler1, Howard Birnbaum, Olga Demler, Ian R H Falloon, Elizabeth Gagnon, Margaret Guyer, Mary J Howes, Kenneth S Kendler, Lizheng Shi, Ellen Walters, Eric Q Wu.   

Abstract

BACKGROUND: To estimate the prevalence and correlates of clinician-diagnosed DSM-IV nonaffective psychosis (NAP) in a national household survey.
METHODS: Data came from the United States National Comorbidity Survey Replication (NCS-R). A screen for NAP was followed by blinded sub-sample clinical reappraisal interviews. Logistic regression was used to impute clinical diagnoses to respondents who were not re-interviewed. The method of Multiple Imputation (MI) was used to estimate prevalence and correlates.
RESULTS: Clinician-diagnosed NAP was well predicted by the screen (area under the curve [AUC] = .80). The MI prevalence estimate of NAP (standard error in parentheses) is 5.0 (2.6) per 1000 population lifetime and 3.0 (2.2) per 1000 past 12 months. The vast majority (79.4%) of lifetime and 12-month (63.7%) cases met criteria for other DSM-IV hierarchy-free disorders. Fifty-eight percent of 12-month cases were in treatment, most in the mental health specialty sector.
CONCLUSIONS: The screen for NAP in the NCS-R greatly improved on previous epidemiological surveys in reducing false positives, but coding of open-ended screening scale responses was still needed to achieve accurate prediction. The lower prevalence estimate than in total-population incidence studies raises concerns that systematic nonresponse bias causes downward bias in survey prevalence estimates of NAP.

Entities:  

Mesh:

Year:  2005        PMID: 16023620      PMCID: PMC2847859          DOI: 10.1016/j.biopsych.2005.04.034

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  33 in total

Review 1.  Epidemiology of schizophrenia: the global burden of disease and disability.

Authors:  A Jablensky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2000       Impact factor: 5.270

2.  Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.

Authors:  A Jablensky; N Sartorius; G Ernberg; M Anker; A Korten; J E Cooper; R Day; A Bertelsen
Journal:  Psychol Med Monogr Suppl       Date:  1992

3.  Comparison of the family history with the family study method: report from the Camberwell Collaborative Psychosis Study.

Authors:  N J Davies; P C Sham; C Gilvarry; P B Jones; R M Murray
Journal:  Am J Med Genet       Date:  1997-02-21

4.  Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule.

Authors:  H G Hwu; E K Yeh; L Y Chang
Journal:  Acta Psychiatr Scand       Date:  1989-02       Impact factor: 6.392

5.  The family history approach to diagnosis. How useful is it?

Authors:  N C Andreasen; J Rice; J Endicott; T Reich; W Coryell
Journal:  Arch Gen Psychiatry       Date:  1986-05

6.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

7.  Accuracies and inaccuracies of the family history method: a multivariate approach.

Authors:  M A Roy; D Walsh; K S Kendler
Journal:  Acta Psychiatr Scand       Date:  1996-04       Impact factor: 6.392

8.  The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures.

Authors:  L N Robins; J Wing; H U Wittchen; J E Helzer; T F Babor; J Burke; A Farmer; A Jablenski; R Pickens; D A Regier
Journal:  Arch Gen Psychiatry       Date:  1988-12

9.  Lifetime prevalence of psychiatric disorders in Edmonton.

Authors:  R C Bland; H Orn; S C Newman
Journal:  Acta Psychiatr Scand Suppl       Date:  1988

10.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

View more
  117 in total

Review 1.  Prevalence and impact of substance use among emerging adults with serious mental health conditions.

Authors:  Ashli J Sheidow; Michael McCart; Kristyn Zajac; Maryann Davis
Journal:  Psychiatr Rehabil J       Date:  2012

2.  When functional capacity and real-world functioning converge: the role of self-efficacy.

Authors:  Veronica Cardenas; Stephanie Abel; Christopher R Bowie; Denisse Tiznado; Colin A Depp; Thomas L Patterson; Dilip V Jeste; Brent T Mausbach
Journal:  Schizophr Bull       Date:  2012-02-10       Impact factor: 9.306

3.  Economic inequality is related to cross-national prevalence of psychotic symptoms.

Authors:  Sheri L Johnson; Erik Wibbels; Richard Wilkinson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-09-14       Impact factor: 4.328

4.  The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Emil F Coccaro; Maurizio Fava; Savina Jaeger; Robert Jin; Ellen Walters
Journal:  Arch Gen Psychiatry       Date:  2006-06

5.  Relation of self-weighing to future weight gain and onset of disordered eating symptoms.

Authors:  Paul Rohde; Danielle Arigo; Heather Shaw; Eric Stice
Journal:  J Consult Clin Psychol       Date:  2018-08

6.  Translocator protein (TSPO) and stress cascades in mouse models of psychosis with inflammatory disturbances.

Authors:  Daisuke Fukudome; Lindsay N Hayes; Travis E Faust; Catherine A Foss; Mari A Kondo; Brian J Lee; Atsushi Saito; Shin-Ichi Kano; Jennifer M Coughlin; Atsushi Kamiya; Martin G Pomper; Akira Sawa; Minae Niwa
Journal:  Schizophr Res       Date:  2018-02-03       Impact factor: 4.939

7.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011

8.  Non-psychiatric hospitalization length-of-stay for patients with psychotic disorders: A mixed methods study.

Authors:  Guy M Weissinger; J Margo Brooks Carthon; Bridgette M Brawner
Journal:  Gen Hosp Psychiatry       Date:  2020-07-31       Impact factor: 3.238

9.  Hallucinations in visually impaired individuals: an analysis of the National Comorbidity Survey Replication.

Authors:  Yoshihiro Kinoshita; Masao Tsuchiya; Norito Kawakami; Toshi A Furukawa; David Kingdon
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-26       Impact factor: 4.328

Review 10.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.